Contact Us
Home
UK-Swiss Grant Awarded to NEUROQUANT Project for Advancing Alzheimer’s Research, Diagnosis and Treatment 

UK-Swiss Grant Awarded to NEUROQUANT Project for Advancing Alzheimer’s Research, Diagnosis and Treatment 

Sign up for Updates
Sign up for Updates

We are thrilled to announce that the project NEUROQUANT – Neurovascular MR coil powered by quantitative neuroimaging technologies for Alzheimer’s disease diagnosis, prognosis, and therapy monitoring, has been awarded a prestigious grant through a joint initiative from Innovate UK and Innosuisse – Swiss Innovation Agency. Skope is one of the project partners, joining forces with MR CoilTech, Gold Standard Phantoms, and Hôpitaux Universitaires Genève. 

This highly competitive program, which focuses on advancing life sciences, AI, semiconductor applications, and quantum technologies, aims to foster UK-Swiss collaboration in emerging fields. The NEUROQUANT project will develop an innovative MR coil, powered by quantitative neuroimaging technologies, to advance Alzheimer’s disease diagnosis, prognosis, and therapy monitoring. 

With Alzheimer’s disease posing a significant global health challenge, this project will play a crucial role in improving diagnostic accuracy and patient outcomes. By leveraging ultra-high field MRI technology at 7 Tesla, the project aims to revolutionize the field by enabling higher spatial resolution and quantitative analysis of the entire brain. This cutting-edge research will not only deepen the understanding of neurodegenerative diseases but also support the development of more effective therapies and drugs. The NEUROQUANT project represents a major step forward in the fight against Alzheimer’s, with the potential to impact millions of lives worldwide.